company background image
MNKD

MannKind NasdaqGM:MNKD Stock Report

Last Price

US$4.61

Market Cap

US$1.2b

7D

4.5%

1Y

7.5%

Updated

05 Dec, 2022

Data

Company Financials +
MNKD fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

MNKD Stock Overview

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.

MannKind Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MannKind
Historical stock prices
Current Share PriceUS$4.61
52 Week HighUS$4.86
52 Week LowUS$2.49
Beta1.77
1 Month Change30.60%
3 Month Change28.77%
1 Year Change7.46%
3 Year Change277.87%
5 Year Change51.65%
Change since IPO-93.45%

Recent News & Updates

Mannkind Corporation: Ready For Your Biotech Portfolio

Sep 01

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19
New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19
New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Aug 14
US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

Feb 22
Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

Shareholder Returns

MNKDUS BiotechsUS Market
7D4.5%3.2%1.1%
1Y7.5%-6.5%-17.6%

Return vs Industry: MNKD exceeded the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: MNKD exceeded the US Market which returned -14.9% over the past year.

Price Volatility

Is MNKD's price volatile compared to industry and market?
MNKD volatility
MNKD Average Weekly Movement8.0%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: MNKD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: MNKD's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1991349Michael Castagnahttps://www.mannkindcorp.com

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.

MannKind Corporation Fundamentals Summary

How do MannKind's earnings and revenue compare to its market cap?
MNKD fundamental statistics
Market CapUS$1.21b
Earnings (TTM)-US$97.51m
Revenue (TTM)US$76.23m

15.9x

P/S Ratio

-12.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MNKD income statement (TTM)
RevenueUS$76.23m
Cost of RevenueUS$52.81m
Gross ProfitUS$23.42m
Other ExpensesUS$120.93m
Earnings-US$97.51m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.37
Gross Margin30.72%
Net Profit Margin-127.93%
Debt/Equity Ratio-158.6%

How did MNKD perform over the long term?

See historical performance and comparison